Cargando…
Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
Autores principales: | Martin-Blondel, Guillaume, Marcelin, Anne-Genevieve, Soulié, Cathia, Kaisaridi, Sofia, Lusivika-Nzinga, Clovis, Dorival, Céline, Nailler, Laura, Boston, Anaïs, Melenotte, Cléa, Cabié, André, Choquet, Christophe, Coustillères, François, Martellosio, Jean-Philippe, Gaube, Géraldine, Trinh-Duc, Albert, Ronchetti, Anne-Marie, Pourcher, Valerie, Chauveau, Marie, Lacombe, Karine, Peiffer-Smadja, Nathan, Housset, Pierre, Perrot, Aurore, Pialoux, Gilles, Martin, Aurélie, Dubee, Vincent, Devaux, Mathilde, Frey, Jérôme, Cazanave, Charles, Liblau, Roland, Carrat, Fabrice, Yordanov, Youri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254651/ https://www.ncbi.nlm.nih.gov/pubmed/35803386 http://dx.doi.org/10.1016/j.jinf.2022.06.033 |
Ejemplares similares
-
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022) -
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir
por: Martin-Blondel, Guillaume, et al.
Publicado: (2023) -
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023) -
Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022) -
Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination
por: Lusivika-Nzinga, Clovis, et al.
Publicado: (2017)